Dr. Dalton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 USF magnolia Drive
Tampa, FL 33612Phone+1 813-745-4673
Summary
- Dr. William Dalton is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He is also the Founder of M2Gen. He received his medical degree from Indiana University School of Medicine and has been in practice for 37 years. He specializes in hematologic oncology and is experienced in myeloma, health information, and medical informatics. He was a past CEO, and Cancer Center Director of the Moffitt Cancer Center (2002-1012).
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Clinical Pharmacology, 1983 - 1985- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1983 - 1985
- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1981 - 1983
Indiana University School of MedicineInternship, Internal Medicine, 1980 - 1981- Indiana University School of MedicineClass of 1980
Indiana University School of MedicinePhD, Toxicology/Pharmacology, 1972 - 1976- University of New MexicoBA, Chemistry/Philosophy, 1967 - 1971
Certifications & Licensure
AZ State Medical License 1981 - 2024
FL State Medical License 2000 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American Association for the Advancement of Science (AAAS), 2018
- Florida Inventors Hall of Fame Florida Inventors HOF, 2016
- Fellow, National Academy of Inventors 2013
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsCombination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancerCharles W. Taylor, William S. Dalton, Kurt Mosley, Robert T. Dorr, Sydney E. Salmon
Breast Cancer Research and Treatment. 1997-01-01 - 1918 citationsBortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G. Richardson, Pieter Sonneveld, Michael W. Schuster, D. Irwin, Edward A. Stadtmauer
The New England Journal of Medicine. 2005-06-16 - 392 citationsA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G. Richardson, Emily A. Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust
Blood. 2006-11-15
Research History
- CEO M2Geninformatics research, cancer genomics2012 - 2022
- CEO and Center Director, Moffitt Cancer Center and University of ArizonaMechanisms of drug resistance in cancer with emphasis on the tumor microenvironment and myeloma and breast cancer1985 - 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
